國藥現代(600420.SH):子公司原料藥硫辛酸獲得境外註冊證書
格隆匯12月14日丨國藥現代(600420.SH)公佈,公司全資子公司國藥集團威奇達藥業有限公司(以下簡稱“國藥威奇達”)分別獲得印度健康家庭福利部、韓國食品藥品安全部簽發的硫辛酸原料藥註冊證書。
硫辛酸是一種有力的新型抗氧化劑,又稱萬能抗氧劑,可以支持人體細胞中葡萄糖的活動,有強力抗氧化作用,可清除體內的遊離基,幫助保持心臟及其它內臟的健康。根據PDB數據庫顯示,2020年全球硫辛酸原料藥消耗量447.644噸,2020年全球硫辛酸製劑銷售額5.405億美元。硫辛酸原料藥國內主要生產廠家有蘇州富士萊醫藥股份有限公司、江蘇同禾藥業有限公司等。本次國藥威奇達用於硫辛酸原料藥在印度和韓國認證註冊的費用投入約人民幣20.40萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.